FAS and cancer: Collectively, these results indicate that JTT did not alter systemic FasL levels but was associated with a modest, statistically significant reduction of CD95 expression on NK cells in cancer patients, implying possible stabilization of NK-cell survival within an apoptosis-prone immune milieu.